Press Releases - Archive



Shareholder Tools


 
Press Releases - Archive
Date Title and Summary View
Nov 10, 2014 SOUTH SAN FRANCISCO, Calif., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, today reported financial results for the quarter ended September 30, 2014. A key highlight for the third quarter...
Oct 29, 2014 SOUTH SAN FRANCISCO, Oct. 29, 2014 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, announced today that it will present at the 2014 Credit Suisse Healthcare Conference in Phoenix, Arizona. Kenneth Hillan, Chief ...
Sep 17, 2014 SOUTH SAN FRANCISCO, Calif., Sept. 17, 2014 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, announced today that the first patient has been enrolled in a Phase 3 clinical trial of plazomicin to treat infections ...
Aug 11, 2014 SOUTH SAN FRANCISCO, Calif., Aug. 11, 2014 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, today reported financial results for the quarter ended June 30, 2014. During the second quarter, the majority of Ach...
Jul 14, 2014 SOUTH SAN FRANCISCO, Calif., July 14, 2014 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, today announced the appointment of Ian Friedland, M.D. as its Chief Medical Officer. In this position, Ian's responsibil...
May 12, 2014 SOUTH SAN FRANCISCO, Calif., May 12, 2014 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, today reported financial results for the quarter ended March 31, 2014. The quarter was highlighted by the initiation ...
Apr 7, 2014 SOUTH SAN FRANCISCO, Calif., April 7, 2014 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, announced today that it will present at the 13th Annual Needham Healthcare Conference in New York, New York. Kenneth Hil...
Apr 2, 2014 SOUTH SAN FRANCISCO, Calif., April 2, 2014 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, announced today that Dr. Chris Boerner has joined Achaogen's Board of Directors. Dr. Boerner currently serves as Executi...
Mar 17, 2014 SOUTH SAN FRANCISCO, Calif., March 17, 2014 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, announced today the closing of its initial public offering of 6,900,000 shares of its common stock at a price to the pu...
Mar 12, 2014 SOUTH SAN FRANCISCO, Calif., March 12, 2014 (GLOBE NEWSWIRE) -- Achaogen, Inc., a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, announced today the pricing of its initial public offering of 6,000,000 shares of its common stock at a price to the public of $12.00...
Page: FirstPrevious ...
12
NextLast
= add release to Briefcase